Adverum Biotech
Gabriel Quitoriano has a diverse work experience in the biotechnology and healthcare industry. Gabriel started their career as a Clinical Development Consultant at Allergan in May 2020 and worked there until July 2021. In June 2021, they joined Syneos Health as a Medical Scientist, where they worked until June 2022. Currently, Gabriel is working at Adverum Biotechnologies, where they started in June 2022 as a Senior Clinical Data Manager and later promoted to Associate Director of Clinical Science & Data Management in July 2023.
Gabriel Quitoriano has a Doctor of Pharmacy degree (PharmD) from the University of California, San Francisco. Gabriel also holds a Bachelor of Science degree (BS) in Molecular Toxicology from the University of California, Berkeley.
This person is not in any offices
Adverum Biotech
9 followers
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.